Latest revenue
$5.8M
as of 2026-03-31
Latest net income
$-309.0K
as of 2026-03-31
Net margin
-5.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.7M
- Enterprise value
- $4.7M
- P/E (trailing)
- 3.4×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.16
- 52-wk low
- $0.01
- Beta
- —
- Shares out
- 52.2M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
ITEM 1. BUSINESS BUSINESS Our Holding Company Structure and China Business Operations The figure below illustrates our corporate structure, including our major subsidiaries and other subsidiaries as of the reporting date of this annual report. CN Healthy Tech Group Corp.is a holding company without substantive operations, with the Group’s core business being managed by its domestic wholly-owned subsidiaries (together, the “Group”). These entities focus on developing, manufacturing, and marketing premium health foods driven by AI-powered biotechnology and biotech innovation. By integrating modern biotechnology with traditional Chinese medicine principles, the Group addresses the market’s…
AI summary unavailable — showing raw filing excerpt
Generated from UCFIW's filing dated 2026-03-31
Key risks
ITEM 1A. RISK FACTORS There are many factors that affect our business and results of operations, some of which are beyond our control. The following is a description of some important factors that may cause the actual results of operations in future periods to differ materially from those currently expected or desired. Risks Related to the Trading Halt As of October 1, 2025, in accordance with Nasdaq’s oral notice, our securities have been suspended from trading on Nasdaq. As of the date of this annual report, our securities have not resumed trading on Nasdaq, which may have a material adverse impact on the value or liquidity of investors holding our securities. As disclosed in our Form 8-K…
AI summary unavailable — showing raw filing excerpt
Generated from UCFIW's filing dated 2026-03-31
Profitability
Return on equity
-33.2%
118.9%Return on assets
1.9%
526.5%Leverage
Debt / equity
-18.57×
95.3%Debt / assets
105.7%
5.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $5.8M | +20.8% | $-309.0K | -468.9% | -5.3% |
Q3 2025 2025-09-30 | $7.9M | +84.2% | $3.3M | +618.5% | 42.3% |
Q2 2025 2025-06-30 | — | — | $19.8K | -95.9% | — |
Q1 2025 2025-03-31 | $4.8M | — | $83.8K | -82.3% | 1.7% |
Q4 2024 2024-12-31 | — | — | $-45.1K | — | — |
Q3 2024 2024-09-30 | $4.3M | — | $465.5K | +439.5% | 10.8% |
Q2 2024 2024-06-30 | — | — | $481.9K | +899.0% | — |
Q1 2024 2024-03-31 | — | — | $473.4K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Food and Kindred Products · SIC 2000
Your notes
Keep private notes on UCFIW — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for UCFIW in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns UCFIW
No institutional holdings on file for UCFIW yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once UCFIW's latest filing finishes processing.